CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 30 enrolled
Drug / intervention
Pregabalin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01511640
NCT01511640Early Ph 1Completed
CompareCT.gov

Behavioral Effects of Drugs (Outpatient)(43)

Joshua A. Lile, Ph.D.·interventional·Posted Jan 18, 2012·Updated Sep 10, 2021

In Brief

A Early Phase 1 clinical trial evaluating Pregabalin and Placebo for Cannabis-use Disorders. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis-use Disorders
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 18, 2012
Enrollment StartFeb 1, 2017
Primary CompletionMar 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 14.5 years ago

Interventions

Pregabalindrug

pregabalin 2x daily for duration of study

Placebodrug

placebo 2x daily for duration of study